[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2022011576A - Moduladores de nlrp3. - Google Patents

Moduladores de nlrp3.

Info

Publication number
MX2022011576A
MX2022011576A MX2022011576A MX2022011576A MX2022011576A MX 2022011576 A MX2022011576 A MX 2022011576A MX 2022011576 A MX2022011576 A MX 2022011576A MX 2022011576 A MX2022011576 A MX 2022011576A MX 2022011576 A MX2022011576 A MX 2022011576A
Authority
MX
Mexico
Prior art keywords
nlrp3 modulators
nlrp3
modulators
disorders
diseases
Prior art date
Application number
MX2022011576A
Other languages
English (en)
Inventor
Jason Harris
Raju Mohan
John Nuss
Shendong Yuan
Original Assignee
Zomagen Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zomagen Biosciences Ltd filed Critical Zomagen Biosciences Ltd
Publication of MX2022011576A publication Critical patent/MX2022011576A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Burglar Alarm Systems (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)

Abstract

En el presente documento se encuentran moduladores de NLRP3 y métodos para utilizar moduladores de NLRP3 en el tratamiento de enfermedades, trastornos o condiciones. En el presente documento también se describen composiciones farmacéuticas que contienen dichos compuestos.
MX2022011576A 2020-03-16 2021-03-15 Moduladores de nlrp3. MX2022011576A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062990363P 2020-03-16 2020-03-16
PCT/US2021/022397 WO2021188450A1 (en) 2020-03-16 2021-03-15 Nlrp3 modulators

Publications (1)

Publication Number Publication Date
MX2022011576A true MX2022011576A (es) 2022-10-18

Family

ID=77747550

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011576A MX2022011576A (es) 2020-03-16 2021-03-15 Moduladores de nlrp3.

Country Status (15)

Country Link
US (3) US11603375B2 (es)
EP (1) EP4121059A4 (es)
JP (1) JP2023518044A (es)
KR (1) KR20220154165A (es)
CN (1) CN115605209A (es)
AR (1) AR121573A1 (es)
AU (1) AU2021237477A1 (es)
BR (1) BR112022018480A2 (es)
CA (1) CA3175729A1 (es)
CL (1) CL2022002531A1 (es)
CO (1) CO2022014499A2 (es)
IL (1) IL296488A (es)
MX (1) MX2022011576A (es)
TW (1) TW202200584A (es)
WO (1) WO2021188450A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4121059A4 (en) 2020-03-16 2023-12-13 Zomagen Biosciences Ltd NLRP3 MODULATORS
JP2024508728A (ja) * 2021-02-10 2024-02-28 ハンジョウ イノゲート ファーマ カンパニー リミテッド Ｎｌｒｐ３阻害剤としての化合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2119705A1 (en) * 2008-05-14 2009-11-18 AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. 3-Aminocarbozole compound, pharmaceutical composition containing it and preparation method therefor
WO2010028116A1 (en) * 2008-09-08 2010-03-11 Merck Serono S.A. Macrocyclics pyrimidines as aurora kinase inhibitors
WO2016115054A2 (en) * 2015-01-13 2016-07-21 Vivreon Biosciences, Llc Modulators of ca2+ release-activated ca2+ (crac) channels and pharmaceutical uses thereof
HUE055755T2 (hu) 2015-02-16 2021-12-28 Univ Queensland Szulfonolkarmabidok és rokon vegyületeik valamint felhasználásuk
US11858922B2 (en) 2016-02-16 2024-01-02 The University Of Queensland Sulfonylureas and related compounds and use of same
WO2017184604A1 (en) 2016-04-18 2017-10-26 Ifm Therapeutics, Inc Compounds and compositions for treating conditions associated with nlrp activity
AU2018210525B2 (en) * 2017-01-23 2022-06-02 Genentech, Inc. Chemical compounds as inhibitors of interleukin-1 activity
JP7072586B2 (ja) * 2017-05-24 2022-05-20 ザ ユニバーシティ オブ クィーンズランド 新規な化合物及び使用
HRP20220195T1 (hr) 2017-07-07 2022-04-15 Inflazome Limited Novi spojevi sulfonamid karboksamida
CN111093773A (zh) 2017-08-15 2020-05-01 英夫拉索姆有限公司 作为nlrp3抑制剂的磺酰脲和磺酰硫脲
EP3668842A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
ES2927851T3 (es) 2017-10-17 2022-11-11 Novartis Ag Sulfonamidas y composiciones de las mismas para tratar afecciones asociadas con la actividad de NLRP
GB201721185D0 (en) 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
EP3759089A1 (en) * 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
MA53172A (fr) * 2018-07-20 2021-05-26 Hoffmann La Roche Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
EP3870565A1 (en) 2018-10-24 2021-09-01 Novartis AG Compounds and compositions for treating conditions associated with nlrp activity
US20220259170A1 (en) 2019-07-17 2022-08-18 Zomagen Biosciences Ltd Nlrp3 modulators
KR20220064364A (ko) 2019-07-17 2022-05-18 조마젠 바이오사이언시즈 엘티디 다발성 경화증(ms)의 치료를 위한 nlpr3 조절제로서의 n-((1,2,3,5,6,7-헥사하이드로-s-인다센-4-일)카바모일)-4,5,6,7-테트라하이드로벤조푸란-2-설폰아미드 유도체 및 관련 화합물
EP4121059A4 (en) 2020-03-16 2023-12-13 Zomagen Biosciences Ltd NLRP3 MODULATORS

Also Published As

Publication number Publication date
CN115605209A (zh) 2023-01-13
IL296488A (en) 2022-11-01
US20210292336A1 (en) 2021-09-23
KR20220154165A (ko) 2022-11-21
CO2022014499A2 (es) 2023-02-16
US20230183258A1 (en) 2023-06-15
TW202200584A (zh) 2022-01-01
CL2022002531A1 (es) 2023-03-31
AU2021237477A1 (en) 2022-10-13
EP4121059A1 (en) 2023-01-25
AR121573A1 (es) 2022-06-15
CA3175729A1 (en) 2021-09-23
JP2023518044A (ja) 2023-04-27
US20240101571A1 (en) 2024-03-28
US11603375B2 (en) 2023-03-14
BR112022018480A2 (pt) 2022-11-29
EP4121059A4 (en) 2023-12-13
WO2021188450A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
MX2021009246A (es) Inmunomoduladores, composiciones y metodos de los mismos.
MX2022009762A (es) Moduladores del purinorreceptor 3 p2x (p2x3).
MX2022000712A (es) Moduladores de nlrp3.
MX2021011723A (es) Ligandos de pseudocinasa tyk2.
MX2022016422A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
NZ757081A (en) Somatostatin modulators and uses thereof
MX2019000588A (es) Moduladores de la somatostatina y usos de los mismos.
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2022001874A (es) Receptores agonistas no peptidicos de somatostatina tipo 5 y usos de los mismos.
MX2022005563A (es) Ligandos de la pseudoquinasa tyk2.
MX2023009685A (es) Inhibidores de tyk2 y sus usos.
MX2021009555A (es) Ligandos de pseudocinasa tyk2.
MX2023012981A (es) Compuestos para inhibir o degradar proteinas objetivo, composiciones que los comprenden, metodos para su preparacion y metodos para usarlos.
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2020007586A (es) Proceso de fabricacion de moduladores de somatostatina.
MX2023009682A (es) Inhibidores de tyk2 y sus usos.
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
MX2023009723A (es) Inhibidores de tyk2 y sus usos.
MX2021013602A (es) Inhibidores de jak.
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
MX2021002916A (es) Pirfenidona enriquecida con deuterio y métodos para su uso.
WO2018183631A8 (en) Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
MX2021008941A (es) Moduladores gpr35.
MX2022011576A (es) Moduladores de nlrp3.